Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for purifying caspofungin precursor pneumocandin B0 component

A purification method and caspofungin technology, applied in the field of purification and caspofungin synthesis, can solve problems such as complicated operation, lower product yield, increased difficulty, etc., and achieve simple purification steps, high production feasibility, and equipment less demanding effect

Active Publication Date: 2014-08-27
CHENGDU YATU BIOLOGICAL TECH
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

If PB 0 If the purity is too low, it will directly affect the yield of each subsequent chemical reaction product, and bring considerable difficulties to the refining and purification of the final product caspofungin, so the preparation of high-purity PB 0 Components are the key to the synthesis and purification of caspofungin
due to PB 0 The components are obtained through microbial fermentation, and the microbial fermentation products have more components, plus PB 0 The structure of the components is complex and unstable to heat and alkali, so it is necessary to prepare high-purity PB 0 Components add to the difficulty
[0004] Currently, pneumocandinB has been 0 Reports on component purification, but the existence or purification effect is not ideal, or the operation is extremely complicated, resulting in a decrease in product yield, making it difficult to achieve large-scale production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for purifying caspofungin precursor pneumocandin B0 component

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] 5g PB 0 The crude components were dissolved in 500ml of 45% ethanol (V / V), which also contained 1‰ formic acid (V / V), and then the pH value was adjusted to 3.0 with formic acid, and 500ml of filtrate was obtained by filtration, and the filtrate was reversed HPLC analysis, the main peak (including PB 0 , PC 0 Components, the two show the same chromatographic peak in reversed-phase chromatography) The content of the component is 3.62g, normal phase HPLC analysis (PB 0 , PC 0 Components can be separated), PB 0 The content of the components was 2.43 g, and the above filtrate was applied to a reverse phase column.

[0029] C18 reversed-phase column material (Fuji Corporation, Japan) Specifications: Lot.No.HU00200, Pro. No.SMB100, Size: 20 / 45um.

[0030] Weigh 300g of C18 reversed-phase column material, load the column with 95% ethanol (V / V) solution, and then equilibrate the column with 45% ethanol, containing 1‰ formic acid ((V / V) solution. After loading, use 50% ethan...

Embodiment 2

[0035] 5g PB 0 The crude component was dissolved in 500ml of 45% ethanol (V / V) solution, then adjusted to pH 4.0 with formic acid, and filtered to obtain 500ml of filtrate, which was analyzed by reverse phase HPLC, the main peak (containing PB 0 , PC 0 Components, the two show the same chromatographic peak in reversed-phase chromatography) The content of the component is 3.62g, normal phase HPLC analysis (PB 0 , PC 0 Components can be separated), PB 0 The content of the components was 2.43 g, and the above filtrate was applied to a reverse phase column.

[0036] C18 reversed-phase column material (Fuji Corporation, Japan) Specifications: Lot.No.HU00200, Pro. No.SMB100, Size: 20 / 45um.

[0037]Weigh 300g of C18 reverse-phase column material, pack the column with 95% ethanol solution, and then equilibrate the column with 45% ethanol containing 1‰ formic acid ((V / V) solution. After loading the sample, use 50% ethanol (V / V) (Which contains 1‰ formic acid (V / V)) to wash the col...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a method for purifying a caspofungin precursor pneumocandin B0 component, and the method comprises the following steps of: carrying out reversed-phase column chromatography on a PB0 component crude product, collecting and carrying out reduced-pressure concentration to obtain a semi-pure product; carrying out normal phase column chromatography on the PB0 semi-pure product obtained in the step 1 to obtain high-purity PB0 component; and carrying out positive and negative phase liquid phase analysis, wherein the chromatographic purity is more than 95%. Compared with the prior art, the method has the beneficial effects that a normal phase column and a reversed-phase column are used for purifying the PB0 component, so that the purification steps are simple, the purification effect is good, the requirements for equipment are low, large-scale production is realized, and the production feasibility is high; and particularly, the PB0 component separated by the method is high in yield, but is lower in cost.

Description

technical field [0001] The present invention relates to the synthesis and purification of caspofungin, in particular to the purification method of caspofungin precursor. Background technique [0002] Caspofungin (caspofungin) is the first new type of echinocandin antifungal drug approved for marketing. It is a semi-synthetic cyclic lipid compound with a relative molecular weight of 1213.42. Its precursor compound pneumocandinB 0 (PB 0 ) is extracted from Glarea lozoyensis. The target of caspofungin is the glucan synthase in the fungal cell wall, which is different from the traditional antifungal drugs that act on ergosterol in the fungal plasma membrane. Compared with the current three types of systemic antifungal drugs: polyenes (amphotericin B), pyrroles (such as ketoconazole, fluconazole, itraconazole), and fluoropyrimidines, it shows a wider range of antifungal agents. Antibacterial spectrum: It is effective against most Candida and other antifungal drug-resistant fu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06C07K1/20C07K1/16
Inventor 朱辉张翠英邹敬源朱春燕龙燕黄运昌杨益陈茂林杨旭成
Owner CHENGDU YATU BIOLOGICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com